← back to database
Invests across the life-sciences development continuum in biotherapeutics, medical devices, and healthcare products addressing significant unmet clinical needs.
Stage focus
Specialization
Generalist / Specialist
Specialist
Latest fund size
US$200 million target (Fund V)
Latest fund vintage
2026
Investing team
Beni RovinskiManaging Director
Daniel HétuManaging Director
Danielle KarakasAnalyst
Gerry BrunkManaging Partner
Isabelle HarrisAssociate
Lu HanPartner
Nikhil ThattePartner
Peter van der VeldenExecutive Chairman
Suman RaoPrincipal
Notable investments
Zymeworks, Aurinia Pharmaceuticals, G1 Therapeutics, Endotronix, OpSens Medical